SEC Form 4 · accession 0001104659-17-052298
Amphastar Pharmaceuticals, Inc. · AMPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard K Prins
Director
Period of report
Aug 14, 2017
Accepted (ET)
Aug 16, 2017 · 6:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001297184
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 14, 2017 | M | 5,000 | $10.77 | A | 33,844 | D | |
| Common StockF1 | Aug 14, 2017 | S | 5,000 | $14.7994 | D | 28,844 | D | |
| Common Stock | Aug 15, 2017 | M | 5,000 | $10.77 | A | 33,844 | D | |
| Common StockF2 | Aug 15, 2017 | S | 5,000 | $14.8174 | D | 28,844 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $10.77 | Aug 14, 2017 | M | 5,000 | D | — | Dec 15, 2017 | Common Stock | 5,000 | 5,000 | D |
| Stock Option (right to buy)F3 | $10.77 | Aug 15, 2017 | M | 5,000 | D | — | Dec 15, 2017 | Common Stock | 5,000 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $14.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- F2The reported price in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $14.65 to $14.97 per share, inclusive.
- F3Shares subject to the option are fully vested and immediately exercisable.